176 related articles for article (PubMed ID: 16582877)
1. Lipid phosphatases as drug discovery targets for type 2 diabetes.
Lazar DF; Saltiel AR
Nat Rev Drug Discov; 2006 Apr; 5(4):333-42. PubMed ID: 16582877
[TBL] [Abstract][Full Text] [Related]
2. Lipid phosphatases as a possible therapeutic target in cases of type 2 diabetes and obesity.
Sasaoka T; Wada T; Tsuneki H
Pharmacol Ther; 2006 Dec; 112(3):799-809. PubMed ID: 16842857
[TBL] [Abstract][Full Text] [Related]
3. PTEN and SHIP2 phosphoinositide phosphatases as negative regulators of insulin signalling.
Vinciguerra M; Foti M
Arch Physiol Biochem; 2006 Apr; 112(2):89-104. PubMed ID: 16931451
[TBL] [Abstract][Full Text] [Related]
4. Pi 3-kinase and its up- and down-stream modulators as potential targets for the treatment of type II diabetes.
Jiang G; Zhang BB
Front Biosci; 2002 Apr; 7():d903-7. PubMed ID: 11897556
[TBL] [Abstract][Full Text] [Related]
5. PTEN and SHIP2 regulates PI3K/Akt pathway through focal adhesion kinase.
Gupta A; Dey CS
Mol Cell Endocrinol; 2009 Oct; 309(1-2):55-62. PubMed ID: 19501627
[TBL] [Abstract][Full Text] [Related]
6. SHIP2: an emerging target for the treatment of type 2 diabetes mellitus.
Baumgartener JW
Curr Drug Targets Immune Endocr Metabol Disord; 2003 Dec; 3(4):291-8. PubMed ID: 14683460
[TBL] [Abstract][Full Text] [Related]
7. ["SHIP2 and insulin signaling: what is its role in the pathogenesis and treatment of type 2 diabetes?"].
Schurmans S
Bull Mem Acad R Med Belg; 2003; 158(7-9):335-9; discussion 340. PubMed ID: 15132004
[TBL] [Abstract][Full Text] [Related]
8. SHIP2 and its involvement in various diseases.
Suwa A; Kurama T; Shimokawa T
Expert Opin Ther Targets; 2010 Jul; 14(7):727-37. PubMed ID: 20536411
[TBL] [Abstract][Full Text] [Related]
9. Impact of Src homology 2-containing inositol 5'-phosphatase 2 on the regulation of insulin signaling leading to protein synthesis in 3T3-L1 adipocytes cultured with excess amino acids.
Murakami S; Sasaoka T; Wada T; Fukui K; Nagira K; Ishihara H; Usui I; Kobayashi M
Endocrinology; 2004 Jul; 145(7):3215-23. PubMed ID: 15044364
[TBL] [Abstract][Full Text] [Related]
10. [Mechanism of insulin action and diabetes mellitus].
Ogawa W; Kasuga M
Seikagaku; 2003 Oct; 75(10):1332-44. PubMed ID: 14635525
[No Abstract] [Full Text] [Related]
11. [Involvement of phosphoinositide 3-kinases and phosphoinositide phosphatases in immune responses, glucose metabolism and tumorigenesis].
Sasaki T; Sasaki J; Suzuki A; Penninger JM
Tanpakushitsu Kakusan Koso; 2001 Sep; 46(12):1820-9. PubMed ID: 11552264
[No Abstract] [Full Text] [Related]
12. SH2-containing inositol phosphatase 2 negatively regulates insulin-induced glycogen synthesis in L6 myotubes.
Sasaoka T; Hori H; Wada T; Ishiki M; Haruta T; Ishihara H; Kobayashi M
Diabetologia; 2001 Oct; 44(10):1258-67. PubMed ID: 11692174
[TBL] [Abstract][Full Text] [Related]
13. Normalization of prandial blood glucose and improvement of glucose tolerance by liver-specific inhibition of SH2 domain containing inositol phosphatase 2 (SHIP2) in diabetic KKAy mice: SHIP2 inhibition causes insulin-mimetic effects on glycogen metabolism, gluconeogenesis, and glycolysis.
Grempler R; Zibrova D; Schoelch C; van Marle A; Rippmann JF; Redemann N
Diabetes; 2007 Sep; 56(9):2235-41. PubMed ID: 17596404
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulin-induced metabolic actions in 3T3-L1 adipocytes via its 5'-phosphatase catalytic activity.
Wada T; Sasaoka T; Funaki M; Hori H; Murakami S; Ishiki M; Haruta T; Asano T; Ogawa W; Ishihara H; Kobayashi M
Mol Cell Biol; 2001 Mar; 21(5):1633-46. PubMed ID: 11238900
[TBL] [Abstract][Full Text] [Related]
15. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells.
Choi Y; Zhang J; Murga C; Yu H; Koller E; Monia BP; Gutkind JS; Li W
Oncogene; 2002 Aug; 21(34):5289-300. PubMed ID: 12149650
[TBL] [Abstract][Full Text] [Related]
16. [Development of new antidiabetic drugs through the advanced knowledge of molecular biology in insulin signal transduction].
Kobayashi M; Hori H; Kawahara J
Nihon Rinsho; 2001 Nov; 59(11):2179-85. PubMed ID: 11712404
[TBL] [Abstract][Full Text] [Related]
17. Reversal of denervation-induced insulin resistance by SHIP2 protein synthesis blockade.
Bertelli DF; Ueno M; Amaral ME; Toyama MH; Carneiro EM; Marangoni S; Carvalho CR; Saad MJ; Velloso LA; Boschero AC
Am J Physiol Endocrinol Metab; 2003 Apr; 284(4):E679-87. PubMed ID: 12453826
[TBL] [Abstract][Full Text] [Related]
18. Impact of lipid phosphatases SHIP2 and PTEN on the time- and Akt-isoform-specific amelioration of TNF-alpha-induced insulin resistance in 3T3-L1 adipocytes.
Ikubo M; Wada T; Fukui K; Ishiki M; Ishihara H; Asano T; Tsuneki H; Sasaoka T
Am J Physiol Endocrinol Metab; 2009 Jan; 296(1):E157-64. PubMed ID: 19001549
[TBL] [Abstract][Full Text] [Related]
19. Dual role of SRC homology domain 2-containing inositol phosphatase 2 in the regulation of platelet-derived growth factor and insulin-like growth factor I signaling in rat vascular smooth muscle cells.
Sasaoka T; Kikuchi K; Wada T; Sato A; Hori H; Murakami S; Fukui K; Ishihara H; Aota R; Kimura I; Kobayashi M
Endocrinology; 2003 Sep; 144(9):4204-14. PubMed ID: 12933696
[TBL] [Abstract][Full Text] [Related]
20. SHIPing news: a new way to keep your weight down.
Birnbaum MJ
Cell Metab; 2005 Feb; 1(2):90-2. PubMed ID: 16054050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
